Medical Oncologist
Tagrisso outcomes
Osimertinib Success Rate: — An Honest Look at the Numbers
If you have just been prescribed osimertinib and want to know what the numbers really mean, this page is for you. The trial data is real and the outcomes are meaningful — and understanding what a median actually tells you changes how you read it.
Medically reviewed by Dr. T. Raghavender Reddy, Medical Oncologist, MBBS · DM (Medical Oncology) · MD (Radiation Oncology) · Last reviewed August 2026
- What the median is — Half the patients in a trial did better than the median number. It describes a group midpoint, not an individual prediction.
- Response and survival are different — Whether the tumour shrinks and how long control lasts are two separate measures — both matter, and both can be asked about directly.
- The range is what matters for you — Every published median has a wide spread around it. Your position in that range depends on factors specific to your cancer and your health.
- Your scan result is your data — How your tumour responded on your most recent imaging is more personally relevant than any trial average.
17+
Cancer Specialists
on Panel
on Panel
96.9%
Breast Cancer
Survival Rate*
Survival Rate*
15,000+
Patients
Treated
Treated
4.8★
Google Rating
(800+ reviews)
(800+ reviews)
Published trials show osimertinib controls EGFR-mutated lung cancer for longer than older EGFR drugs, and that improvement is measured in years rather than months. The number most often quoted is the median — the midpoint of the trial group. Half the patients in those trials did better than the median; ask your oncologist what it means for your situation.
How does your team track whether osimertinib is working?
Baseline imaging before you start
Before treatment begins, your team arranges a scan — usually CT, sometimes PET-CT — to establish exactly how large and how widespread the cancer is. Every future scan is measured against this.
First response scan after the initial cycles
After the first few cycles of treatment, a scan checks whether the tumour has shrunk. A meaningful shrinkage is called a response, and it is the earliest sign that osimertinib is working for your specific cancer.
Regular monitoring scans throughout treatment
Scans continue every few months while you are on osimertinib. Your team is looking for any sign that the cancer has started growing again. The time from starting treatment until that point is your progression-free survival.
Resistance testing if the drug stops controlling the cancer
If growth is detected, a liquid biopsy or new tissue sample identifies how the cancer has changed. That result guides the next treatment step — there are usually options to consider.
What does a median mean — and what does it not mean?
A median is the midpoint of a group. If you arranged all the trial patients from the one who responded for the shortest time to the one who responded the longest, the median is the person in the exact middle. Half the patients did better than that number; half did not.
It is not a prediction for you. Two people with the same diagnosis can have very different outcomes, and nothing in the trial data tells you in advance which half you will be in.
The range around the median matters as much as the median itself. In the FLAURA trial — which established osimertinib as a first-line treatment — some patients were still on treatment years after the median was reached. That is not unusual: it is part of what the data shows, and it is part of what you are entitled to ask about.
Meet the Specialists
17+ senior cancer specialists. One panel for your case.
Trained at AIIMS, Tata Memorial, and leading international centres. Combined 150+ years of experience. Every complex case is reviewed by 3+ of them — together.
Medical Oncologist
Dr. C. Raghavendra Reddy
MBBS(Gold Medal), DNB(General Medicine), DM(Medical Oncology)(Gold Medal)
Medical Oncologist
Dr. Bharati Devi Gorantla
MBBS, MD(General Medicine), DM(Medical Oncology)(Adyar,Chennai), ECMO, MRCP SCE(UK)
Medical Oncologist
Dr. Owais Mohammed
MBBS, MD (General Medicine), DrNB (Medical Oncology), ECMO, MRCP SCE (Medical Oncology) (UK)
Medical Oncologist
Medical Oncologist
Surgical Oncologist
Dr. Muralidhar Muddusetty
MBBS (AIIMS), MS (Surgery) (AIIMS), DNB (Surgical Oncology), MRCS (Edinburgh)
Surgical Oncologist
Surgical Oncologist
Surgical Oncologist
Dr. Vinay Mamidala
MBBS, MS(General Surgery), M.Ch(Surgical Oncology), FMAS, FARIS(Ongoing)
Surgical Oncologist
Radiation Oncologist
Radiation Oncologist
Radiation Oncologist
Hematologist
Interventional Radiologist
Dr. Mohammed Imran
Surgical Oncologist
Dr. Vajja Sandeep Kumar
MBBS, MS (General Surgery), DrNB (Surgical Oncology), FALS Oncology
Surgical Oncologist
Want a specific doctor for your case? Mention them when booking.
Book Free ConsultationBook an appointment with our specialist
Share your name and number — we'll call you back within 30 minutes to schedule your consultation.
Get a straight answer from a specialist
45 minutes, your reports reviewed, your questions answered in plain language.
Questions to bring to your next appointment
- Ask which trial result applies to your situation: first treatment, after a previous EGFR drug, or after surgery.
- Ask what your tumour response was on the last scan, and by how much it changed.
- Ask what the range of outcomes looks like — not just the median, but how wide the spread is.
- Ask what early signs would tell your team that osimertinib is starting to stop working.
- Ask what the plan is after osimertinib, so the next step is mapped before you reach it.
- Ask whether a liquid biopsy is being used to monitor for early resistance changes.
Why your outcome will not look exactly like the trial average
Clinical trial participants are selected carefully. They typically have good organ function, few other serious illnesses, and met strict entry criteria. Real patients are more varied, and that can shift outcomes in either direction.
Which EGFR mutation you carry also matters. Response patterns differ between the two most common mutations — exon 19 deletion and L858R — and rarer variants may behave differently again. Your oncologist knows which applies to you and can explain what the data shows for your specific mutation.
The trial median is a reference point, not a ceiling. It tells you where the middle of a large studied group landed. It cannot tell you which half you will be in — and that uncertainty applies equally in both directions.
Explore 75 more Lung Cancer Targeted Medicines topics
Drug Deep Dive: Osimertinib (Tagrisso)
- Adjuvant Osimertinib After Lung Cancer Surgery: Three Years of Tablets
- Breathlessness or New Cough on Osimertinib: Recognising Lung Injury (ILD)
- Diet and Nutrition While on Osimertinib
- Drug, Food and Supplement Interactions With Osimertinib
- Fertility, Pregnancy and Contraception on Osimertinib
- Heart Rhythm and Ejection Fraction Changes on Osimertinib
- How Does Osimertinib Work? The Third-Generation EGFR Inhibitor Explained
- How Long Does Osimertinib Take to Work?
- How Long Will You Stay on Osimertinib?
- Osimertinib (Tagrisso): The Complete Patient Guide
- Osimertinib Myths: Clear Scans, Stopping Early and Generic Quality
- Osimertinib Price in India: Brand, Generic and Monthly Cost
- Osimertinib Side Effects: The Complete List and Timeline
- Osimertinib Success Rate and Survival: An Honest Look at the Numbers
- Osimertinib With Chemotherapy: Who Actually Benefits From the Combination?
- Osimertinib and Brain Metastases: Why It Works Inside the Brain
- Osimertinib in Elderly Patients and Those With Other Illnesses
- Osimertinib vs Gefitinib and Erlotinib: Is the Costlier Drug Worth It?
- Rash, Dry Skin and Nail Problems on Osimertinib
- Taking Osimertinib: Food, Timing and What to Do If You Miss a Dose
- Tests and Monitoring While You Are on Osimertinib
- When Osimertinib Stops Working: Resistance and What Comes Next
- Who Is Eligible for Osimertinib? EGFR-Mutant Lung Cancer
- Will Insurance or a Government Scheme Pay for Osimertinib?
- Work, Travel and Daily Life on Osimertinib
Drug Deep Dive: Alectinib (Alecensa)
- Alectinib (Alecensa, Alectinib): The Complete Patient Guide
- Alectinib After Surgery for Early-Stage ALK-Positive Lung Cancer
- Alectinib Myths: Is ALK-Positive Cancer 'Curable'?
- Alectinib Price in India: Brand, Generic and Monthly Cost
- Alectinib Side Effects: The Complete List and Timeline
- Alectinib Success Rate and Survival: An Honest Look at the Numbers
- Alectinib and Brain Metastases: How It Protects the Brain
- Alectinib in Elderly Patients and Those With Other Illnesses
- Alectinib vs Crizotinib vs Lorlatinib: Choosing an ALK Inhibitor
- Diet and Nutrition While on Alectinib
- Do You Need Chemotherapy Alongside Alectinib?
- Drug, Food and Supplement Interactions With Alectinib
- Fertility, Pregnancy and Contraception on Alectinib
- How Does Alectinib Work? The Second-Generation ALK Inhibitor Explained
- How Long Does Alectinib Take to Work?
- How Long Will You Stay on Alectinib?
- Muscle Pain and High CPK on Alectinib: When to Worry
- Severe Sun Sensitivity on Alectinib: Preventing Serious Burns
- Taking Alectinib: Food, Timing and What to Do If You Miss a Dose
- Tests and Monitoring While You Are on Alectinib
- Weight Gain, Constipation and a Slow Pulse on Alectinib
- When Alectinib Stops Working: Resistance and What Comes Next
- Who Is Eligible for Alectinib? ALK-Positive Lung Cancer
- Will Insurance or a Government Scheme Pay for Alectinib?
- Work, Travel and Daily Life on Alectinib
Drug Deep Dive: Gefitinib (Iressa)
- Diarrhoea on Gefitinib: Home Management and Warning Signs
- Diet and Nutrition While on Gefitinib
- Fertility, Pregnancy and Contraception on Gefitinib
- Gefitinib (Iressa, Geftinat, Geftib): The Complete Patient Guide
- Gefitinib Myths: 'It's Only for Poor Patients' and Other Half-Truths
- Gefitinib Plus Chemotherapy: Does Adding Chemo Actually Help?
- Gefitinib Price in India: Brand, Generic and Monthly Cost
- Gefitinib Rash: Why It Appears in Week Two and How to Treat It
- Gefitinib Side Effects: The Complete List and Timeline
- Gefitinib Success Rate and Survival: An Honest Look at the Numbers
- Gefitinib and Antacids: The Interaction That Silently Reduces Absorption
- Gefitinib in Early-Stage vs Advanced Lung Cancer: Different Goals
- Gefitinib in Elderly Patients and Those With Other Illnesses
- Gefitinib vs Osimertinib: Making the Decision When Cost Matters
- How Does Gefitinib Work? The First-Generation EGFR Inhibitor Explained
- How Long Does Gefitinib Take to Work?
- How Long Will You Stay on Gefitinib?
- Raised Liver Enzymes on Gefitinib: What Your LFT Report Means
- T790M Testing After Gefitinib Stops Working: The Next Step Explained
- Taking Gefitinib: Food, Timing and What to Do If You Miss a Dose
- Tests and Monitoring While You Are on Gefitinib
- When Gefitinib Stops Working: Resistance and What Comes Next
- Who Is Eligible for Gefitinib? EGFR-Mutant Lung Cancer
- Will Insurance or a Government Scheme Pay for Gefitinib?
- Work, Travel and Daily Life on Gefitinib
Next step
Still not sure what applies to you?
Send your reports across and a senior medical oncologist will go through what they mean, what is known, and what the options actually are.
Common questions
Frequently asked questions
What is the response rate for osimertinib?
Response rate measures what proportion of patients had their tumour shrink by a defined amount on imaging. In published first-line trials reported by ASCO and ESMO, osimertinib produced a response in a large majority of patients with EGFR-mutated NSCLC — higher than what was seen with older EGFR drugs. The specific figure differs between first-line use, T790M-positive second-line use, and adjuvant use after surgery. Your oncologist can tell you which trial applies to your situation and what the response rate in that trial was.
How long does osimertinib keep working for most people?
Published data endorsed by ASCO and ESMO shows median progression-free survival measured in years when osimertinib is used as a first treatment for EGFR-mutated NSCLC — a meaningful step beyond older drugs in the same class. But the range around that median is wide. Some patients progressed earlier and some were still on treatment years beyond the median. Where any individual lands in that range is not predictable from the trial data alone, and your own scan results are the most relevant guide to how your cancer is responding.
What happens when osimertinib stops working?
Resistance to targeted therapy eventually develops in most people, and osimertinib is no exception. When progression is detected, a liquid biopsy or repeat tissue biopsy looks for the resistance mechanism — the specific change that allowed the cancer to grow again. That result determines what comes next. Some resistance mechanisms can be targeted with other drugs or a clinical trial; others point toward chemotherapy or a combination approach. It is worth asking your oncologist now what the next-line plan looks like, before you reach that point.
Does osimertinib work better when started before any other treatment?
Yes, and the data distinguishes clearly between settings. When osimertinib is the first EGFR drug used — rather than following an older drug in the same class — the outcomes reported in trials are better. There is also a separate adjuvant setting: the ADAURA trial showed that osimertinib after surgery reduces the risk of recurrence in people with early-stage EGFR-mutated NSCLC. If you have been offered osimertinib after surgery, that is a different context from advanced disease, and the data behind the recommendation is different from what you may read in general articles about the drug.
Why do doctors talk about progression-free survival rather than cure?
Most EGFR-mutated lung cancers respond to targeted therapy, but the cancer usually finds ways around the drug over time. Progression-free survival honestly describes what the treatment does — it controls the cancer for a period — without implying the cancer is permanently eliminated. Overall survival, the other key measure, captures the full picture including everything that follows osimertinib. Using these terms is not a signal of pessimism; it is the language of honest measurement. Neither number tells you what will happen to you specifically.
Is osimertinib available at CION?
Osimertinib is administered as day care at CION centres. Your treating oncologist will confirm whether it is the recommended option for your EGFR mutation type and stage. Prescriptions are coordinated through the pharmacy; CION does not supply or stock named drugs directly. Response-assessment imaging such as CT and PET-CT is arranged through partner imaging centres. CION does not provide CAR-T or cell therapy.